McKesson announces OCM solutions to support community-based oncology practices
Comprehensive solution includes services, expertise and technology to support oncology practices. Read More »
Comprehensive solution includes services, expertise and technology to support oncology practices. Read More »
Jonathan Small, C.P.A. and president of Oklahoma Council of Public Affairs (OCPA), recently wrote a “Free Market Friday” op-ed for The Journal Record to promote freedom in the delivery and payment of health care, showing how Oklahoma is better off not accepting funds to support the Affordable Care Act (ACA). Read More »
With health care spending on an upward trajectory, Alex Brill, CEO of economic policy consulting firm Matrix Global Advisors, thinks that value within the sector also must increase. Read More »
The clinical trial will test bococizumab versus a placebo in reducing the risk of a major cardiovascular event. Read More »
Oklahoma consumers enrolled in health plans with insurance deductibles that are yet to be reached and those who are uninsured may bear the high costs of rising drug prices, thanks to a proposed piece of legislation that would give pharmacies permission to disregard negotiated discounts with insurers and transfer the price hikes on to consumers. Read More »
CHANTIX/CHAMPIX compared to bupropion, nicotine patch and placebo; study finds significantly higher abstention rates. Read More »
McKesson Patient Relationship Solutions (MPRS) was a finalist in the eyeforpharma Philadelphia Awards 2016. Read More »
Adding IBRANCE (palbociclib) to letrozole treatment for advanced or metastatic breast cancer improves progression-free survival rate. Read More »
The annual spring conference featured solutions to the changing landscape in health care delivery systems. Read More »
McKesson recently announced that it has been awarded a $139 million, five-year contract from the Department of Defense and the Defense Health Agency for its patient engagement and interoperable secure messaging solution, RelayHealth. Read More »
Pfizer and IBM announced today a novel research partnership that will lead to the development of groundbreaking remote monitoring solutions focused on revolutionizing the care Parkinson’s patients receive. Read More »
The U.S. Food and Drug Administration (FDA) has approved Celltrion’s INFLECTRA (biosimilar infliximab) for all qualified indications of the reference product, Remicade (infliximab). Read More »
Pfizer has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved a new presentation of Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]). Read More »
One pharmaceutical company executive stated that the challenges retail and outpatient pharmacies face in regards to the reimbursement and regulatory environment can be solved by technology. Read More »
Blue Cross and Blue Shield of Illinois (BCBSIL) and Illinois Cancer Specialists (ICS) have announced the very first oncology intensive medical home (IMH) pilot program in Illinois. Read More »
Pfizer and Bristol-Myers Squibb have released the 17 abstracts that the two companies will present at the American College of Cardiology’s 65th Annual Scientific Session (ACC.16) in Chicago on April 2-4. Read More »
McKesson announced this week that it has launched its disaster recovery service that will help health care organizations uphold their mission-critical capabilities when disasters strike. Read More »
Pfizer has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application (MAA) for XELJANZ (tofacitinib citrate) for review. Read More »
Pfizer has announced that it will be presenting new data based on the research of tofacitinib in ulcerative colitis (UC) and Crohn’s disease at the 11th Congress of ECCO, which is scheduled for March 16-19 in Amsterdam. Read More »
Pfizer today released its 2015 integrated annual review, which is an in-depth look at the company’s financial, social and environmental performance. Read More »